Register for the AMCP PIE Webinar on
FormularyDecisions below!
Aceess key information on future drug approvals and therapeutic areas of interest

Overview of Vadadustat, an Investigational Drug for the Treatment of Anemia Due to CKD

Overview of Vadadustat, an Investigational Drug for the Treatment of Anemia Due to CKD Tuesday, February 8, 2022 from 2:00pm to 3:00pm ET.

Anemia, an important and common complication of chronic kidney disease (CKD), imposes a profound impact on patients and is associated with poor clinical outcomes.

Vadadustat is an investigational oral hypoxia-inducible factor propyl hydroxylase inhibitor (HIF-PHI), a novel class of drugs that stimulate endogenous erythropoietin production. This session will cover the mechanism of action as well as the safety and efficacy data of vadadustat for the treatment of anemia due to CKD. Akebia Therapeutics, Inc. has submitted a new drug application to the US Food and Drug Administration for vadadustat.

Vadadustat is not FDA-approved for use in the treatment of anemia due to CKD.

Dr. Margaret Zak
How to register for the webinar
If you already have a FormularyDecisions account:
If you do not have a FormularyDecisions account:

If you are a healthcare decision maker and would like to have access to all webinars, evidence and tools in FormularyDecisions, click here to register. You can also learn more about FormularyDecisions by visiting our website.

Once registered for FormularyDecisions, you can register for the webinar in the Webinars section of the FormularyDecisions home page or here

FormularyDecisions provides US healthcare decision makers with connections to peer community opinions, access to evidence-based resources, and bi-directional communication with life sciences manufacturers.


This webinar is only offered to healthcare decision makers, formulary committees, or other similar entities responsible for selecting healthcare products for coverage or reimbursement. By registering/joining a webinar, you agree not to copy or disseminate any of the information to individuals not approved to receive the information by the FDA Final Guidance document. You also agree that the information shared with you is to be used for the purposes of evaluating products for formulary placement/utilization management and may not be used by you or your company for any other purpose.
You also agree to share the details specified below with the company holding the webinar, for the purpose of evaluating your eligibility to attend the webinar; contacting you as per the company’s compliance regulations, should any information presented change; or in response to a question posed during the webinar. The company may also contact you if you registered for the webinar but did not attend. The details that will be shared are first name, last name, company name, professional degree, position, role, and employer-provided email address.

FormularyDecisions is proud to partner with AMCP to enhance information sharing between healthcare decision makers and life sciences manufacturers through a current, credible, and compliant platform, with the ultimate goal of enhancing the field of formulary decision making and helping improve patient health.